Design, characterization, and evaluation of scFvCD133/rgelonin: A CD133-targeting recombinant immunotoxin for use in combination with photochemical internalization

Cathrine Elisabeth Olsen, Lawrence H. Cheung, Anette Weyergang, Kristian Berg, Daniel A. Vallera, Michael G. Rosenblum, Pål Kristian Selbo

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The objective of this study was to develop and explore a novel CD133-targeting immunotoxin (IT) for use in combination with the endosomal escape method photochemical internalization (PCI). scFvCD133/rGelonin was recombinantly constructed by fusing a gene (scFvCD133) encoding the scFv that targets both non-glycosylated and glycosylated forms of both human and murine CD133/prominin-1 to a gene encoding the ribosome-inactivating protein (RIP) gelonin (rGelonin). RIP-activity was assessed in a cell-free translation assay. Selective binding and intracellular accumulation of scFvCD133/rGelonin was evaluated by flow cytometry and fluorescence microscopy. PCI of scFvCD133/rGelonin was explored in CD133high and CD133low cell lines and a CD133neg cell line, where cytotoxicity was evaluated by the MTT assay. scFvCD133/rGelonin exhibited superior binding to and a higher accumulation in CD133high cells compared to CD133low cells. No cytotoxic responses were detected in either CD133high or CD133low cells after 72 h incubation with <100 nM scFvCD133/rGelonin. Despite a severe loss in RIP-activity of scFvCD133/rGelonin compared to free rGelonin, PCI of scFvCD133/rGelonin induced log-fold reduction of viability compared to PCI of rGelonin. Strikingly, PCI of scFvCD133/rGelonin exceeded the cytotoxicity of PCI of rGelonin also in CD133low cells. In conclusion, PCI promotes strong cytotoxic activity of the per se non-toxic scFvCD133/rGelonin in both CD133high and CD133low cancer cells.

Original languageEnglish (US)
Article number68
JournalJournal of Clinical Medicine
Volume9
Issue number1
DOIs
StatePublished - Jan 2020

Bibliographical note

Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • CD133
  • Cancer stem cells
  • Drug delivery
  • Immunotoxins
  • Photochemical internalization
  • Photodynamic therapy
  • Prominin-1
  • Ribosome-inactivating proteins

Fingerprint

Dive into the research topics of 'Design, characterization, and evaluation of scFvCD133/rgelonin: A CD133-targeting recombinant immunotoxin for use in combination with photochemical internalization'. Together they form a unique fingerprint.

Cite this